Forecast

The analysts' average price target is +1,72€ (+647,83%). The median is +1,72€ (+647,83%).

Buy	8
Hold	4
Sell	1

News Go to news feed

Accuray reports mixed Q4 results: revenue weaker, stock under pressure

Accuray slightly beat adjusted loss guidance with EPS of -$0.02 in Q4 but missed revenue estimates with $100.91 million (‑21% year over year). Product revenue plunged 42% in the quarter, while the service business grew 6% and gross margin improved to 34.8%. Management declined to give formal guidance for 2027 due to geopolitical and tariff-related uncertainties, but announced cost cuts, service growth initiatives and a debt-conversion transaction. The stock fell sharply after the results, and the company’s market position remains weighed down by high debt and persistently weak device sales. » More on de.investing.com
Accuray withdraws full-year guidance after weak quarter and cites geopolitical turbulence

Accuray reported Q3 revenue of $104.8 million (-7%), missed expectations, and recorded adjusted EBITDA of $3.8 million with a GAAP net loss of $11.8 million. The stock fell in after-hours trading and is trading near its 52-week low. Management cites conflicts in the Middle East, uncertainties in China and tariff debates as reasons and has withdrawn the 2026 full-year guidance. The company meanwhile emphasizes ongoing transformation measures with already realized margin improvements and expects further cost improvements for 2027. » More on de.investing.com
Accuray adjusts advisory agreement and cuts cash compensation by 50% to reduce costs

Accuray amended the advisory agreement with Dedication Capital (connected to director Steven F. Mayer): cash fees and minimum premiums for certain periods were reduced by 50%, expected to save at least $362,500. Time-based vesting conditions for 916,336 restricted shares and all performance share awards were deemed satisfied as of April 1; 333,004 remaining shares are scheduled to be issued on October 31, 2026, and the agreement’s termination date was extended to October 31, 2026. The adjustment comes against the backdrop of high debt of $174 million and a market capitalization of $49.75 million; the stock lost 73% in six months but recently gained about 8%. Additionally, Accuray reported Q2 revenue of $102.2 million (below expectations) with EPS of -$0.11, BTIG cut its price target from $4 to $2, and NASDAQ flagged ongoing minimum-price violations. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Accuray has already paid 0,62€ in dividends. The last payout was in June 2022.

Financials

In the last quarter, Accuray had revenue of 88.43m€ and net profit of −1.70m€

(EUR)	Jun 2026	YoY
Revenue	+88.43m	18,28%
Gross profit	+31.14m	5,84%
Net profit	−1.70m	278,50%
EBITDA	+62.21k	99,07%

Fundamentals

Metric	Value
Market capitalization	+27.73m€
Number of shares	118.96m
52-week high/low	+1,80€ - +0,19€
Dividends	No
Beta	1,39
P/E ratio	−0,69
PEG ratio	0,00
P/B ratio	+0,80
P/S ratio	+0,08

Company profile

Accuray Incorporated entwirft, entwickelt, produziert und vertreibt Radiochirurgie- und Strahlentherapiesysteme für die Behandlung von Tumoren in Nord- und Südamerika, Europa, dem Nahen Osten, Indien, Afrika, Japan, China und dem restlichen asiatisch-pazifischen Raum. Das Unternehmen bietet das CyberKnife System an, ein robotergestütztes stereotaktisches Radiochirurgie- und stereotaktisches Strahlentherapiesystem, das für die Behandlung verschiedener Krebsarten und Tumore im Körper eingesetzt wird, z. B. Prostata, Lunge, Gehirn, Wirbelsäule, Leber, Bauchspeicheldrüse und Niere. Das Unternehmen bietet auch das TomoTherapy-System an, einschließlich des Radixact-Systems, das aus einem integrierten Strahlentherapiesystem besteht, das für die Behandlung einer Reihe von Krebsarten entwickelt wurde. Darüber hinaus bietet es Kundendienst, Installation, Schulung und andere professionelle Dienstleistungen nach Vertragsabschluss an. Das Unternehmen vertreibt seine Produkte in erster Linie direkt an Kunden, darunter Krankenhäuser und eigenständige Behandlungseinrichtungen, über seine Vertriebsorganisation sowie an Kunden über Handelsvertreter und Einkaufsgemeinschaften in den Vereinigten Staaten und an Kunden direkt und über Vertriebshändler und Handelsvertreter international. Accuray Incorporated wurde 1990 gegründet und hat seinen Hauptsitz in Sunnyvale, Kalifornien.

Name	Accuray
CEO	Stephen R. LaNeve
Headquarters	Madison, wi USA
Website	accuray.com
Sector	Consumer Discretionary
Industry	Household Durables
IPO	02/08/2007
Employees	990